Showing results (501-510 of 512) with videos related to
Sort By:
Pageof 52
Gut|March 23, 2021
Anti-SARS-CoV-2 antibody responses are attenuated in patients with IBD treated with infliximabNicholas A Kennedy, James R Goodhand, Claire Bewshea, et al.Gut|June 10, 2020
Adaptations to the British Society of Gastroenterology guidelines on the management of acute severe UC in the context of the COVID-19 pandemic: a RAND appropriateness panelShahida Din, Alexandra Kent, Richard C Pollok, et al.Nature Communications|March 17, 2022
Antibody decay, T cell immunity and breakthrough infections following two SARS-CoV-2 vaccine doses in inflammatory bowel disease patients treated with infliximab and vedolizumabSimeng Lin, Nicholas A Kennedy, Aamir Saifuddin, et al.Journal of Crohn'S & Colitis|November 9, 2023
Antibody Responses to Influenza Vaccination are Diminished in Patients With Inflammatory Bowel Disease on Infliximab or TofacitinibZhigang Liu, James L Alexander, Kai Yee Eng, et al.The Lancet. Gastroenterology & Hepatology|September 11, 2022
COVID-19 vaccine-induced antibody and T-cell responses in immunosuppressed patients with inflammatory bowel disease after the third vaccine dose (VIP): a multicentre, prospective, case-control studyJames L Alexander, Zhigang Liu, Diana Muñoz Sandoval, et al.Gut|April 19, 2020
British Society of Gastroenterology guidance for management of inflammatory bowel disease during the COVID-19 pandemicNicholas A Kennedy, Gareth-Rhys Jones, Christopher A Lamb, et al.Eclinicalmedicine|October 16, 2023
Neutralising antibody responses against SARS-CoV-2 Omicron BA.4/5 and wild-type virus in patients with inflammatory bowel disease following three doses of COVID-19 vaccine (VIP): a prospective, multicentre, cohort studyZhigang Liu, James L Alexander, Kaixing Le, et al.United European Gastroenterology Journal|July 11, 2025
Assessment of PredictSURE IBD Assay in a Multinational Cohort of Patients With Inflammatory Bowel DiseaseDahham Alsoud, Nurulamin M Noor, Lea Ann Chen, et al.The Lancet. Gastroenterology & Hepatology|February 25, 2024
A biomarker-stratified comparison of top-down versus accelerated step-up treatment strategies for patients with newly diagnosed Crohn's disease (PROFILE): a multicentre, open-label randomised controlled trialNurulamin M Noor, James C Lee, Simon Bond, et al.BMJ Open|April 17, 2024
Defining predictors of responsiveness to advanced therapies in Crohn's disease and ulcerative colitis: protocol for the IBD-RESPONSE and nested CD-metaRESPONSE prospective, multicentre, observational cohort study in precision medicineNicola J Wyatt, Hannah Watson, Carl A Anderson, et al.Pageof 52